Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease
Identifieur interne : 003F17 ( Main/Exploration ); précédent : 003F16; suivant : 003F18Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease
Auteurs : M. Gentil [France] ; C.-L. Tournier [France] ; P. Pollak [France] ; A. L. Benabid [France]Source :
- European neurology [ 0014-3022 ] ; 1999.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Analysis of Variance, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Articulation Disorders (drug therapy), Articulation Disorders (etiology), Articulation Disorders (physiopathology), Articulation Disorders (therapy), Bilateral, Case study, Chemotherapy, Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dysarthria, Electric Stimulation Therapy, Electrodes, Implanted, Follow-Up Studies, Human, Humans, Instrumental stimulation, Language disorder, Levodopa, Levodopa (administration & dosage), Levodopa (therapeutic use), Lip (physiopathology), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Parkinson disease, Pulse Therapy, Drug, Reaction Time, Subthalamic Nucleus (surgery), Subthalamic nucleus, Tongue (physiopathology), Treatment, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Articulation Disorders, Parkinson Disease.
- etiology : Articulation Disorders.
- physiopathology : Articulation Disorders, Lip, Parkinson Disease, Tongue.
- surgery : Subthalamic Nucleus.
- therapy : Articulation Disorders, Parkinson Disease.
- Analysis of Variance, Electric Stimulation Therapy, Electrodes, Implanted, Follow-Up Studies, Humans, Male, Middle Aged, Pulse Therapy, Drug, Reaction Time, Treatment Outcome.
Abstract
This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001445
- to stream PascalFrancis, to step Curation: 001C00
- to stream PascalFrancis, to step Checkpoint: 001347
- to stream Main, to step Merge: 004661
- to stream PubMed, to step Corpus: 001432
- to stream PubMed, to step Curation: 001391
- to stream PubMed, to step Checkpoint: 001391
- to stream Ncbi, to step Merge: 000073
- to stream Ncbi, to step Curation: 000073
- to stream Ncbi, to step Checkpoint: 000073
- to stream Main, to step Merge: 004359
- to stream Main, to step Curation: 003F17
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease</title><author><name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M." last="Gentil">M. Gentil</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C.-L." last="Tournier">C.-L. Tournier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">99-0528295</idno><date when="1999">1999</date><idno type="stanalyst">PASCAL 99-0528295 INIST</idno><idno type="RBID">Pascal:99-0528295</idno><idno type="wicri:Area/PascalFrancis/Corpus">001445</idno><idno type="wicri:Area/PascalFrancis/Curation">001C00</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001347</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001347</idno><idno type="wicri:doubleKey">0014-3022:1999:Gentil M:effect:of:bilateral</idno><idno type="wicri:Area/Main/Merge">004661</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:10529538</idno><idno type="wicri:Area/PubMed/Corpus">001432</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001432</idno><idno type="wicri:Area/PubMed/Curation">001391</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001391</idno><idno type="wicri:Area/PubMed/Checkpoint">001391</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001391</idno><idno type="wicri:Area/Ncbi/Merge">000073</idno><idno type="wicri:Area/Ncbi/Curation">000073</idno><idno type="wicri:Area/Ncbi/Checkpoint">000073</idno><idno type="wicri:doubleKey">0014-3022:1999:Gentil M:effect:of:bilateral</idno><idno type="wicri:Area/Main/Merge">004359</idno><idno type="wicri:Area/Main/Curation">003F17</idno><idno type="wicri:Area/Main/Exploration">003F17</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease</title><author><name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M." last="Gentil">M. Gentil</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C.-L." last="Tournier">C.-L. Tournier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>INSERM, U 318, Centre Hospitalier Universitaire</s1><s2>Grenoble</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">European neurology</title><title level="j" type="abbreviated">Eur. neurol.</title><idno type="ISSN">0014-3022</idno><imprint><date when="1999">1999</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European neurology</title><title level="j" type="abbreviated">Eur. neurol.</title><idno type="ISSN">0014-3022</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Articulation Disorders (drug therapy)</term><term>Articulation Disorders (etiology)</term><term>Articulation Disorders (physiopathology)</term><term>Articulation Disorders (therapy)</term><term>Bilateral</term><term>Case study</term><term>Chemotherapy</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (therapeutic use)</term><term>Dysarthria</term><term>Electric Stimulation Therapy</term><term>Electrodes, Implanted</term><term>Follow-Up Studies</term><term>Human</term><term>Humans</term><term>Instrumental stimulation</term><term>Language disorder</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Lip (physiopathology)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Parkinson disease</term><term>Pulse Therapy, Drug</term><term>Reaction Time</term><term>Subthalamic Nucleus (surgery)</term><term>Subthalamic nucleus</term><term>Tongue (physiopathology)</term><term>Treatment</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Articulation Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Articulation Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Articulation Disorders</term><term>Lip</term><term>Parkinson Disease</term><term>Tongue</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Articulation Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Electric Stimulation Therapy</term><term>Electrodes, Implanted</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pulse Therapy, Drug</term><term>Reaction Time</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Lévodopa</term><term>Antiparkinsonien</term><term>Trouble langage</term><term>Stimulation instrumentale</term><term>Noyau sousthalamique</term><term>Bilatéral</term><term>Dysarthrie</term><term>Etude cas</term><term>Traitement</term><term>Homme</term><term>Chimiothérapie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Grenoble</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M." last="Gentil">M. Gentil</name></region><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name><name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C.-L." last="Tournier">C.-L. Tournier</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:99-0528295
|texte= Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |